Clinical trial
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
NCT00130442 · Cellxpert Biotechnology Corp., Industry · Completed
Key facts
| NCT number | NCT00130442 |
|---|---|
| Title | Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma |
| Official title | A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma |
| Lead sponsor | Cellxpert Biotechnology Corp., Industry |
| Collaborators | Medigen Biotechnology Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | PI-88 and dacarbazine, dacarbazine or DTIC |
| Enrollment | 134 |
| Start date | Jun 1, 2005 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Aug 15, 2005 |
| Last update posted | Jun 23, 2022 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: